# Silybin (Silybum marianum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/silybin-silybum-marianum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Silybum marianum flavonolignan, Silibinin, Silybin A and B, Silymarin major component, CAS 22888-70-6

## Overview

Silybin (C₂₅H₂₂O₁₀, MW 482.44 g/mol) is a flavonolignan that exerts [hepatoprotective](/ingredients/condition/detox), antioxidant, and [antimicrobial](/ingredients/condition/immune-support) effects by modulating pro-[inflammatory](/ingredients/condition/inflammation) cell-signaling cascades, scavenging [reactive oxygen species](/ingredients/condition/antioxidant), and inhibiting RNA and protein synthesis in susceptible bacteria such as Bacillus subtilis and Staphylococcus epidermidis. In pharmacokinetic studies, a phytosome formulation of silybin (360 mg) achieved a C-max of 860 ± 166 ng/mL compared to 83 ± 15 ng/mL for standard silymarin (336 mg), demonstrating a roughly 10-fold bioavailability advantage for lipid-complexed delivery systems.

## Health Benefits

- **[Hepatoprotect](/ingredients/condition/detox)ion**: Silybin reduces hepatic fibrosis and inflammation by downregulating pro-inflammatory mediators such as TNF-α and NF-κB, and by modulating TGF-β signaling to limit stellate cell activation; it is widely used adjunctively in alcoholic liver disease, toxic liver injury, and non-alcoholic fatty liver disease.
- **[Antioxidant Activity](/ingredients/condition/antioxidant)**: Silybin directly scavenges hydroxyl and peroxyl radicals and upregulates endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase, thereby reducing oxidative damage in hepatocytes and other tissues.
- **[Antimicrobial](/ingredients/condition/immune-support) Effects**: Silybin inhibits RNA polymerase and ribosomal protein synthesis in gram-positive bacteria including Bacillus subtilis and Staphylococcus epidermidis, positioning it as a bioactive scaffold for novel antibacterial strategies.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Modulation**: By suppressing cyclooxygenase-2 (COX-2) expression and reducing interleukin-1β and interleukin-6 levels, silybin attenuates systemic and local inflammatory responses at the molecular level.
- **Antifibrotic Action**: Silybin interferes with hepatic stellate cell proliferation and collagen type I deposition by modulating SMAD signaling downstream of TGF-β1, reducing progressive fibrosis in chronic liver injury models.
- **Potential Anticancer Properties**: Preclinical studies indicate silybin induces cell cycle arrest (G1/S and G2/M phases) and apoptosis in cancer cell lines via p53 stabilization, Bcl-2 downregulation, and caspase-3 activation, though human clinical evidence remains limited.
- **Insulin Sensitization and Metabolic Support**: Silybin has demonstrated improvements in [insulin resistance](/ingredients/condition/weight-management) and lipid metabolism in preclinical and limited clinical settings, potentially via PPAR-γ modulation and inhibition of hepatic lipogenesis.

## Mechanism of Action

Silybin exerts its primary [hepatoprotective](/ingredients/condition/detox) mechanism by inhibiting NF-κB nuclear translocation, thereby suppressing transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (TNF-α, IL-1β, IL-6) and reducing [oxidative stress](/ingredients/condition/antioxidant) through upregulation of Nrf2-mediated antioxidant response elements including heme oxygenase-1 (HO-1) and glutathione synthesis enzymes. Its antifibrotic effect is mediated by blocking TGF-β1/SMAD2/3 signaling in hepatic stellate cells, reducing collagen I and III deposition and matrix metalloproteinase dysregulation. For its [antimicrobial](/ingredients/condition/immune-support) activity, silybin inhibits bacterial RNA polymerase function and disrupts ribosomal assembly, impairing protein synthesis in gram-positive species such as B. subtilis and S. epidermidis. Silybin undergoes extensive phase II conjugation in humans, forming monoglucuronide, diglucuronide, and monosulfate metabolites; the parent compound exhibits weak acidic character with pKa values of 6.63 (5-OH), 7.7–7.95 (7-OH), and 11.0 (20-OH), influencing its membrane permeability and tissue distribution.

## Clinical Summary

The most robust clinical data for silybin concern its pharmacokinetics rather than therapeutic end-points: in six healthy subjects, 240 mg pure silybin yielded C-max values of 0.18–0.62 µg/mL, while enhanced-bioavailability formulations (phytosome, liposome, SMEDDS) improve absorption 3- to 10-fold, with C-max reaching up to 1,310 ng/mL and AUC up to 11,200 ng·h/mL. Clinical trials examining hepatic outcomes in liver disease patients have generally been underpowered (n < 50) and have used mixed silymarin extracts rather than purified silybin, complicating attribution of effect. A 24-week open-label study reported tolerability of silymarin at 700 mg three times daily without significant adverse events, but hard endpoints such as liver histology improvement were not conclusively demonstrated in the available summarized literature. Confidence in silybin's clinical efficacy for liver disease is moderate-to-low pending larger, well-controlled trials using standardized high-bioavailability silybin formulations with pre-specified primary endpoints.

## Nutritional Profile

Silybin is a pure flavonolignan compound (C₂₅H₂₂O₁₀) rather than a whole food; it does not contribute meaningful macronutrients, micronutrients, or calories in supplemental doses. It exists as a near-equal mixture of two diastereoisomers, silybin A and silybin B (approximately 1:1 ratio), with closely related minor constituents isosilybin A and isosilybin B present in the silymarin complex. The compound's lipophilic character (logP approximately 1.8–2.3) results in poor aqueous solubility (~0.04 mg/mL at physiological pH), which is the primary driver of its variable oral bioavailability (estimated 20–50% for standard forms). When delivered as part of the whole silymarin extract, silybin comprises 50–70% of the bioactive flavonolignan content, with silydianin, silychristin, and isosilybins comprising the remainder; phospholipid complexation or nano-encapsulation substantially improves apparent bioavailability.

## Dosage & Preparation

- **Standard Silymarin Extract (Capsule/Tablet)**: Standardized to 70–80% silymarin, providing approximately 50–70% silybin; typical dose 140–420 mg silymarin per day in divided doses; onset of absorption 1–4 hours.
- **Pure Silybin (Pharmaceutical Grade)**: Studied at 240–360 mg per dose in pharmacokinetic trials; bioavailability is limited without a lipid carrier due to poor water solubility.
- **Silybin Phytosome (Phosphatidylcholine Complex)**: 120–360 mg silybin equivalent per dose; achieves approximately 10× higher C-max than standard silymarin; the phytosome form (e.g., Siliphos®) is the preferred formulation for systemic bioavailability.
- **Silybin-Phosphatidylcholine-Vitamin E Complex**: Studied at 47 mg silybin equivalent; produces C-max of ~213 ng/mL versus ~18 ng/mL for standard granules; taken orally with meals to enhance absorption.
- **Liposomal and SMEDDS Formulations**: Emerging delivery systems achieving C-max up to 1,310 ng/mL and AUC up to 11,200 ng·h/mL; not yet widely commercialized.
- **Granule/Powder Form**: Used in some clinical studies as a comparator; lower bioavailability than phytosome but acceptable for gastrointestinal-local effects.
- **Safe Upper Limit**: Doses below 10 g/day have not produced significant adverse events; most therapeutic protocols use 420–700 mg silymarin equivalent daily.

## Safety & Drug Interactions

Silybin and silymarin are exceptionally well-tolerated; clinical studies report no significant adverse effects at doses up to 700 mg silymarin three times daily for 24 weeks, and acute safety data suggest no toxicological concern below 10 g/day. Mild gastrointestinal symptoms (nausea, loose stools, abdominal fullness) have been reported infrequently at higher doses and are generally self-limiting. No clinically significant drug-drug interactions have been documented in the reviewed literature, though theoretical interactions with CYP3A4 and P-glycoprotein substrates exist based on in vitro data, warranting caution with narrow therapeutic index drugs such as certain immunosuppressants and anticoagulants. Pregnancy and lactation safety has not been established in controlled human trials; while traditional use suggests tolerability, the lack of systematic safety data means caution is advised in these populations, and use should follow guidance from a qualified healthcare provider.

## Scientific Research

The clinical evidence base for silybin is predominantly composed of small pharmacokinetic studies in healthy volunteers and limited open-label trials in patients with liver disease, with few large-scale randomized controlled trials isolating silybin from the broader silymarin complex. A pharmacokinetic crossover study in 12 healthy volunteers demonstrated that a silybin-phosphatidylcholine-vitamin E complex (47 mg silybin) achieved a plasma C-max of 213 ng/mL versus 18 ng/mL for standard silymarin granules (58 mg silybin), confirming the absorption advantage of lipid-based formulations. A separate comparison of silybin phytosome (360 mg) versus standard silymarin (336 mg) reported C-max values of 860 ± 166 ng/mL versus 83 ± 15 ng/mL, respectively, with corresponding AUC improvements. While preclinical evidence for [hepatoprotect](/ingredients/condition/detox)ion, anticancer activity, and [antimicrobial](/ingredients/condition/immune-support) effects is substantial, the overall clinical evidence for therapeutic outcomes such as ALT normalization, fibrosis regression, or infection clearance remains preliminary, warranting well-powered RCTs with standardized silybin formulations.

## Historical & Cultural Context

Milk thistle (Silybum marianum), the botanical source of silybin, has been used in European herbal medicine for over 2,000 years, with records tracing back to Dioscorides and Pliny the Elder, who documented its use for liver and biliary complaints in the first century CE. Medieval European herbalists recommended preparations of milk thistle seeds for jaundice, gallbladder disorders, and as a tonic for nursing mothers to promote milk production, the latter giving rise to the common name 'milk thistle.' In Ayurvedic and Unani systems, related thistle preparations were used for hepatic and splenic conditions, and German Commission E formally approved standardized silymarin extract for supportive treatment of toxic liver damage and as adjuvant therapy in chronic [inflammatory](/ingredients/condition/inflammation) liver diseases in the late twentieth century. The isolation and structural characterization of silybin as the principal active constituent of silymarin was achieved in the 1960s–1970s by Wagner and colleagues, marking the transition from whole-plant preparations to purified pharmaceutical-grade compounds.

## Synergistic Combinations

Silybin combined with phosphatidylcholine (as in the phytosome formulation) dramatically enhances oral bioavailability through formation of a lipid-soluble complex that improves transcellular membrane transport, achieving up to 10-fold greater plasma exposure than standard silymarin. Co-administration with vitamin E, as studied in the silybin-phosphatidylcholine-vitamin E complex, may provide complementary [antioxidant protection](/ingredients/condition/antioxidant) via tocopherol-mediated lipid peroxidation inhibition, synergizing with silybin's Nrf2-dependent antioxidant enzyme induction. Silybin has also been explored in combination with berberine and other polyphenols for metabolic liver disease, with preclinical data suggesting additive effects on lipid [metabolism](/ingredients/condition/weight-management) and insulin signaling, though clinical confirmation of these stack pairings remains limited.

## Frequently Asked Questions

### What is the difference between silybin and silymarin?

Silymarin is the standardized extract from milk thistle seeds consisting of a family of flavonolignans including silychristin, silydianin, isosilybins, and silybin; silybin is the single most abundant and pharmacologically active constituent of silymarin, comprising 50–70% of the extract. When you see a silymarin supplement standardized to 70–80%, roughly half of that standardized fraction consists of silybin A and silybin B diastereoisomers. Pharmaceutical-grade pure silybin is also available for research and clinical applications where precise dosing is required.

### How much silybin should I take per day for liver support?

Most clinical studies and traditional European protocols use 140–420 mg of silymarin (standardized extract) per day in two to three divided doses, which corresponds to approximately 70–300 mg of silybin depending on standardization. For enhanced-bioavailability phytosome formulations, studied doses of 120–360 mg silybin equivalent per day have been used safely. Because bioavailability varies dramatically between formulations—phytosome achieving roughly 10× the plasma levels of standard silymarin—selecting a clinically validated form and consulting a healthcare provider for dose optimization is advisable.

### Why is silybin's bioavailability so poor, and how can it be improved?

Silybin has low aqueous solubility (approximately 0.04 mg/mL at physiological pH) and modest intestinal permeability due to its polyphenolic structure, resulting in erratic absorption and C-max values as low as 5–18 ng/mL for standard silymarin granules. Complexing silybin with phosphatidylcholine (phytosome technology) creates a lipid-compatible molecular complex that dramatically improves transcellular absorption, raising C-max to 860 ± 166 ng/mL in comparative studies. Other bioavailability-enhancing strategies under investigation include liposomal encapsulation, self-microemulsifying drug delivery systems (SMEDDS), and nanoparticle formulations, some achieving AUC values up to 11,200 ng·h/mL.

### Does silybin have antimicrobial properties?

Yes, silybin demonstrates in vitro antimicrobial activity against certain gram-positive bacteria, particularly Bacillus subtilis and Staphylococcus epidermidis, through inhibition of bacterial RNA polymerase and disruption of ribosomal protein synthesis. These mechanisms are distinct from classical antibiotic classes, and silybin has been explored as a structural scaffold for developing novel antibacterial agents. However, clinical evidence for silybin as a standalone antimicrobial therapy in humans is currently lacking, and it should not be used as a substitute for established antibiotic treatments.

### Is silybin safe to take long-term, and are there any drug interactions?

Silybin and silymarin are among the best-tolerated botanical compounds documented; a 24-week clinical study using 700 mg silymarin three times daily reported no significant adverse effects, and acute toxicity data indicate safety below 10 g/day. Minor gastrointestinal symptoms such as nausea or loose stools may occur at higher doses but are generally self-limiting. No clinically confirmed drug-drug interactions have been documented in humans, though in vitro data suggest potential modulation of CYP3A4 and P-glycoprotein, so caution is warranted with narrow therapeutic index medications such as tacrolimus, warfarin, or certain antiretrovirals; pregnancy and lactation safety has not been established in controlled trials.

### What does clinical research show about silybin's effectiveness for fatty liver disease?

Clinical studies demonstrate that silybin significantly reduces hepatic steatosis, liver enzyme levels (ALT and AST), and markers of fibrosis in both alcoholic and non-alcoholic fatty liver disease (NAFLD) patients. Meta-analyses support its use as an adjunctive therapy, with benefits typically emerging over 8–12 weeks of supplementation at therapeutic doses. However, while evidence is promising, most guidelines recommend silybin alongside lifestyle modifications rather than as monotherapy.

### Who benefits most from silybin supplementation?

Individuals with existing liver compromise—including those with alcoholic liver disease, hepatitis C, cirrhosis, drug-induced liver injury, or NAFLD—show the greatest therapeutic benefit from silybin. People with elevated liver enzymes, metabolic dysfunction, or exposure to hepatotoxic substances may also benefit from its hepatoprotective mechanisms. Those with healthy livers typically experience preventive benefits only, making silybin most valuable for individuals with documented or high-risk liver conditions.

### How do different delivery forms of silybin affect its therapeutic effectiveness?

Standardized silymarin extracts (70–80% silybin) remain the most studied form, though newer phospholipid complexes (phytosome technology) and micellized formulations show 2–10× greater bioavailability compared to unencapsulated silybin. Combination formulas pairing silybin with milk thistle co-constituents (silydianin, silychristin) may offer synergistic hepatoprotective effects, though individual silybin content typically determines clinical outcomes. For maximum efficacy, phospholipid-bound or micellized forms are preferable, especially for patients with compromised absorption.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*